Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
Recruiting · NCT07216391 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 2 | 2026-09-09 | NCT07216391 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 617 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Barbara Davis Center | Aurora | United States | 9 |
| Benaroya Research Institute | Seattle | United States | 9 |
| Columbia University | New York | United States | 154 |
| University of Florida | Gainesville | United States | 144 |
| University of Pittsburgh | Pittsburgh | United States | 9 |
| Yale University | New Haven | United States | 44 |